Report Overview

The Acne drug market size in Kenya stood at around USD xx billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Acne Vulgaris is the most common dermatological condition of the pilosebaceous glands. Rise in androgen/oestrogen levels during puberty triggers the onset of this condition by enlarging oil glands under the skin. This leads to excessive sebum production, which breaks down cell walls in pores leading to bacterial invasion. The prevalence of acne was 11.2% in general population of rural western Kenya. The majority of those affected by acne were women. Acne Vulgaris pose a significant threat to patients well-being, mental health, confidence, and social participation.



Market Drivers

The market is majorly driven by the increase in the incidence of Acne in Kenya. Acne is the most common skin condition among young population. Kenya is considered a young country and has approximately 20% of its population in 15-24 years age group.

Increasing prevalence of acne, especially in teenagers and young women, coupled with rising consciousness about looks and appearance among women are among some of the major factors driving growth of acne drug market in Kenya.

Moreover, other factors that fuel the market include unhealthy urban lifestyle, presence of robust acne medications in pipeline and easy availability of acne medications in the market.

However, the side effects caused by several drugs are restraining market growth. Decline in the dermatological consultations because of lockdown measures due to the COVID-19 outbreak may also hamper the growth of Acne drug market.